Grifols and CRB invest € 4 M in Mecwins technology
Progenika Biopharma, a Grifols Company, and CRB Inverbío undersign EUR 2 million of Mecwins’ capital increase each. The total investment of EUR 4 million will allow Mecwins to complete the introduction of the technology into the Life Sciences Market and to conduct clinical trials to demonstrate the diagnostic capabilities of its ultra-sensitive technology (a million times higher than that used in routine clinical practice).
Mecwins was founded in 2008 by Dr. Javier Tamayo and Dr. Montserrat Calleja, Bionanomechanics group leaders from the Institute of Microelectronics of Madrid (IMM – CSIC). Since then, the Coampany has developed innovative technology for nanomechanical sensing. The technology was the groundwork for the technical improvements that led Mecwins to their ultrasensitive detection system.
#Healthcare biotech; #Community of Madrid